These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15968293)

  • 1. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies.
    Ji SQ; Chen HR; Yan HM; Wang HX; Liu J; Zhu PY; Xiao MH; Xun CQ
    Bone Marrow Transplant; 2005 Aug; 36(4):349-54. PubMed ID: 15968293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion.
    Chen HR; Ji SQ; Wang HX; Yan HM; Zhu L; Liu J; Xue M; Xun CQ
    Exp Hematol; 2003 Nov; 31(11):1019-25. PubMed ID: 14585364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A clinical study of haploidentical and G-CSF primed bone marrow transplantation by using CD25 for aGVHD prophylaxis].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Oct; 10(5):447-51. PubMed ID: 12513746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia.
    Ji SQ; Chen HR; Wang HX; Yan HM; Zhu L; Liu J; Xue M; Xun CQ
    Bone Marrow Transplant; 2002 Dec; 30(12):861-6. PubMed ID: 12476277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
    Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update.
    Arcese W; Picardi A; Santarone S; De Angelis G; Cerretti R; Cudillo L; Pennese E; Bavaro P; Olioso P; Dentamaro T; Cupelli L; Chierichini A; Ferrari A; Mengarelli A; Tirindelli MC; Testi M; Di Piazza F; Di Bartolomeo P;
    Bone Marrow Transplant; 2015 Jun; 50 Suppl 2():S24-30. PubMed ID: 26039203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A clinical study of haploidentical transplantation using granulocyte colony-stimulating factor stimulating donor bone marrow].
    Chen H; Ji S; Wang H
    Zhonghua Nei Ke Za Zhi; 2001 Nov; 40(11):760-3. PubMed ID: 11930684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow.
    Neudorf SM; Rybka W; Ball E; Blatt J; Bloom E; Corey S; deMagalhaes-Silverman M; Koehler M; Lister J; Mierski J; Mirro J; Pincus S; Wilson J; Wollman M; Donnenberg AD
    J Hematother; 1997 Aug; 6(4):351-9. PubMed ID: 9377073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD.
    Wawer A; Laws HJ; Dilloo D; Göbel U; Burdach S
    Klin Padiatr; 2004; 216(3):169-75. PubMed ID: 15175962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
    O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
    Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis.
    Huang R; Tu S; Deng L; Kang Q; Song C; Li Y
    Hematology; 2015 Jul; 20(6):313-9. PubMed ID: 25321657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients.
    Blaise D; Olive D; Hirn M; Viens P; Lafage M; Attal M; Stoppa AM; Gabert J; Gastaut JA; Camerlo J
    Bone Marrow Transplant; 1991 Aug; 8(2):105-11. PubMed ID: 1933050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
    Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
    Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.